Asco 2020 – abstract dump triggers first moves
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
The annual Asco meeting can prove a volatile time for drug stocks and, despite the cancer conference going virtual this year, 2020 still looks likely to deliver a healthy flow of market-moving news.
Abstracts were made public yesterday, and the early beneficiaries included Allogene, which provided the first look at data on an off-the-shelf Car-T project, while Immunogen got a boost from encouraging results with its lead antibody-drug conjugate. On the downside, however, Cytomx, Arvinas and Macrogenics all fell heavily in early trade.
A pullback in Macrogenics was almost inevitable after the company’s market cap more than tripled last week on a surprisingly detailed update on the trials that it would present (Macrogenics scoops its Asco bounce, May 7, 2020). And with later cuts of the data due at the conference, compared with what was released in the abstracts, much remains to be learned.
The two projects that will feature remain very early, of course, and toxicity in particular will be a key focus. But even with a 9% dip this morning, Macrogenics shares remain at a two-year high.
Arvinas fell more heavily, down 17% on data probably being held up against MGC018, Macrogenics’ anti-B7-H3 bispecific in prostate cancer. ARV-110 is mechanistically very different – it is described as a protein degrader of the androgen receptor – but a PSA response in only two of 15 patients seems underwhelming.
The abstract also details two serious adverse events, including a case of renal failure, which appears to be linked to statin use.
With a 38% drop this morning Cytomx looks to be one of the biggest casualties; the company has presentations on three projects at Asco. Disappointment around lack of efficacy data on the highest-profile one might be playing a part; the abstract on BMS-986249, a CTLA-4 probody partnered with Bristol-Myers Squibb, contains only toxicity data.
A number of projects that are attempting to improve on the known toxicities of CTLA-4 inhibition will be on show at Asco, including bispecifics from Xencor and Alphamab. Shares in the latter climbed 10% in Hong Kong today.
Two further Cytomx abstracts concerns earlier-stage wholly owned conjugates. Response rates appear underwhelming, and ocular toxicity is confirmed as a signal to watch with CX-2009; with the company’s probody technology still largely unvalidated, investors must hope that the full presentations can reverse some of this pre-Asco pessimism.
On the up
The biggest pre-Asco bounce appears to go to Allogene, which opened 25% higher on encouraging data in its lead Car-T project, ALLO-501, in lymphoma.
Also enjoying a bounce was Immunogen, which will present data on an antibody-drug conjugate against folate receptor alpha (FRα). A 61% ORR in patients with high FRα expression looks encouraging.
Other presentations that will be attracting interest include Amgen’s latest data on its Kras project AMG 510. In colorectal cancer the ORR looks to have improved slightly from that presented at Esmo, climbing from 8% (1/12) to 12% (3/25), although the limited responses in tumours beyond colorectal or lung cancers could provide further ammunition to those who believe that the potential has been overblown.
Elsewhere, new data from projects recently acquired by big pharma could pull some crowds. Gilead will provide an update on magrolimab, for which it paid $4.9bn; the numbers point to some improvement from an update at Ash.
And Merck & Co provides the first new data on MK-6482, which cost it $1.1bn via the Peloton takeover. The HIF-2α inhibitor achieved a 28% response rate in a rare form of renal cell carcinoma.
With much of the headline-grabbing data saved for the conference, and the late-breaking abstract texts still under wraps, there is much still to come from Asco. But investors have plenty to chew through in the meantime.
|Outside the main stage: some notable Asco presentations|
|Merck KGaA||Bintrafusp alfa||TGF-beta/PD-1 bispecific: 2yr follow-up in 2L NSCLC||9558|
|Lilly||Selpercatinib||Data on label more relevant to comparison with Blueprint's pralsetinib||3584|
|Astrazeneca/Daiichi Sankyo||Enhertu||Destiny-CRC01: ORR 45.3% (24/53) in Her2+ mCRC||4000|
|Astrazeneca/Daiichi Sankyo||Enhertu||Destiny-Gastric01: ORR 51.3% vs 13.3%||4513|
|Astrazeneca/Daiichi Sankyo||Enhertu||Destiny-Lung01 interim results: ORR 61.9%, 14mth mPFS||9504|
|Merck & Co||Keytruda||Keynote-355, in 1L TNBC, confirms success only in PD-L1-high tumours.||1000|
|Bristol-Myers Squibb||CC-92480||Novel CELMoD agent in rrMM: ORR 48% at therapeutic dose||8500|
|Bluebird/Bristol||Ide-cel||Update on pivotal Karmma data, shows slight improvement vs last update||8503|
|Autolus||Auto3 (CD19xCD22)||Longer follow-up from Alexander trial; later cutoff due at Asco||8001|
|Bristol-Myers Squibb/ Cytomx||BMS-986249||CTLA-4 probody; tox data only in abstract, consistent with CTLA-4 blockade||3058|
|Allogene||ALLO-501||r/r NHL initial results of Alpha study: ORR 78% (7/9)||8002|
|Aveo||Tivozanib||Final OS of Tivo-3 trial due at Asco, currently at HR=0.99||5062|
|Macrogenics||MGC018 (anti-B7-H3 ADC)||Awaiting later cuts at Asco; responses reported in SCLC, NSCLC and mCRPC||3071|
|Macrogenics||MGD013 (anti-Lag3 & PD-1 bispecific MAb)||Awaiting later cuts at Asco; among 41 pts, 3 PRs in TNBC, mesothelioma & gastric cancer||3004|
|Genmab||Epcoritamab (GEN3013)||CD20 bispecific, relevant to Regeneron and Roche projects||8009|
|Cytomx||CX-2029||Probody conjugate of MMAE and CD71; 1/32 PR in squamous NSCLC||3502|
|Cytomx||CX-2009||Probody conjugate of DM4 and CD166; 8/92 PRs in breast, ovarian and H&N||526|
|Iovance||Lifileucel (LN-144)||One month extra data from previous presentation; awaiting later cut at Asco||10006|
|Xencor||XmAB20717||PD-1-CTLA-4 bispecific: 1/34 CR in melanoma at highest dose tested||e15001|
|Alphamab||KN046||PD-L1-CTLA-4 bispecific; ORR 12% (3/25)||3020|
|Arvinas||ARV-110||2 of 15 pts achieved confirmed PSA declines of >50%; tox signal||3500|
|Immunogen||Mirvetuximab soravtansine||FRα-DM4 ADC: 61% ORR in 33 high FRα-expressing tumors||6004|
|Gilead||Magrolimab||From Forty Seven; slight improvement on Ash numbers||7507|
|Amgen||AMG 510||Colorectal cancer: 12% ORR at 960mg||4018|
|Amgen||AMG 510||Solid tumours excl CRC or NSCLC: 14% ORR (3/22)||3511|
|Blueprint||Pralsetinib||Updated Arrow data look weaker on ORR than Lilly, stronger on duration||9515|
|Merck & Co||MK-6482||Peloton buy: phase II in Von Hippel-Lindau-associated ccRCC||5003|
A look at the late-breakers can be found here: Asco 2020 starts to take shape. The Asco virtual conference takes place on May 29-31.